Previous 10 | Next 10 |
Novavax reported an underwhelming Q1 earnings card. Despite reiterating its FY22 guidance, the consensus estimates have been downgraded. The market is losing confidence in management's ability to deliver. Therefore, if Novavax continues to miss the estimates, we believe it could lead ...
Today, we revisit advance wound care name Organogenesis Holdings for the first time since late in 2020. This small cap healthcare concern is already profitable and continues to build out its product portfolio. A full investment analysis follows in the paragraphs below. For f...
Over the years, Exelixis' esteemed management successfully ramped up cabozantinib sales beyond the blockbuster range. Through many ongoing aggressive cabozantinib advancements, you can expect this blockbuster to grow by several more folds in revenue in the next few years. Meanwhil...
Cryoport is not just any biotech company, as it is banking on the booming logistic businesses for the cell/gene therapy sector. Leveraging the powerful merger and acquisition approach, Cryoport has been enjoying leaping top-line growth year-over-year. Despite a temporary setback, ...
Shares of Cue Biopharma have tumbled some 75% since November 2021, as somewhat underwhelming data from slowly developing Phase 1 trials are at fault. The company’s Immuno-STAT platform is a novel approach to immuno-oncology that should reduce risks associated with systemic expo...
Mitapivat got approved for PK deficiency. They have multiple label expansion potential. Current prices are attractively low. For further details see: Agios: Approved Product, Upcoming Catalysts
In a down market, you can pick up the same fundamentally robust companies at a fraction of their intrinsic value. As an orphan disease innovator, BioMarin is enjoying significant and substantial revenue increases from its approved assets. Nevertheless, the company is aggressively ...
DTIL has been lagging due to poor durability data. The company stock has been lagging due to market indifference. I see no prospects here. For further details see: Precision Bio: Another CAR-T Laggard With No Solid Prospects
By selling its only growth asset, Viatris has turned out to be a cigar butt investment that still has many puffs left in it due to its strong free cash flow. Debt remains a concern, but the company continues to deleverage thanks to its strong free cash flow and has accelerated the pro...
A phase 2a study using Lomecel-B for Alzheimer's Disease is currently enrolling patients; a prior phase 1 study established excellent safety profile with some efficacy. The global Alzheimer's Disease market could reach $25 billion by 2027. Lomecel-B has several shots on goal; besi...
News, Short Squeeze, Breakout and More Instantly...
ProShares UltraShort Nasdaq Biotechnology Company Name:
BIS Stock Symbol:
NASDAQ Market:
A look at the top 10 most actives in the United States Maxeon Solar Technologies Ltd. (MAXN) rose 3.6% to $0.2493 on volume of 118,503,418 shares Qualigen Therapeutics Inc. (QLGN) rose 94.8% to $0.4 on volume of 100,863,101 shares AgriFORCE Growing Systems Ltd. (AGRI) rose 20.0% to $0.098...
A look at the top 10 most actives in the United States Kazia Therapeutics Limited (KZIA) rose 106.5% to $1.38 on volume of 71,739,314 shares Renalytix plc (RNLX) rose 41.4% to $0.4269 on volume of 54,892,134 shares Maxeon Solar Technologies Ltd. (MAXN) fell 7.4% to $0.1951 on volume of 45...
A look at the top 10 most actives in the United States Agrify Corporation (AGFY) rose 164.2% to $0.6658 on volume of 125,460,313 shares NVIDIA Corporation (NVDA) fell 2.9% to $122.88 on volume of 51,163,891 shares Crown Electrokinetics Corp. (CRKN) fell 0.3% to $0.04097 on volume of 44,45...